Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
The ONCT news page on Stock Titan aggregates press releases and other coverage related to Oncternal Therapeutics, Inc., a company that has been described in its own communications as a clinical-stage biopharmaceutical developer of oncology therapies. These news items trace both the evolution of its investigational pipeline and its later strategic decisions, giving investors and researchers a consolidated view of the company’s trajectory.
Earlier news focuses on clinical and operational updates for programs such as ONCT-534, an investigational dual-action androgen receptor inhibitor evaluated in metastatic castration-resistant prostate cancer, and ONCT-808, an autologous CAR T cell therapy targeting ROR1 in relapsed or refractory aggressive B-cell lymphoma. Releases detail dose-escalation cohorts, safety and tolerability observations, interim efficacy signals based on measures like prostate-specific antigen levels, and protocol amendments in ongoing Phase 1/2 studies.
Other articles describe the broader pipeline, including zilovertamab, a monoclonal antibody targeting ROR1 studied in combination with ibrutinib and in investigator-initiated trials, and ONCT-216, a small-molecule inhibitor of ETS family oncoproteins with regulatory designations for Ewing sarcoma. These pieces provide context on the scientific rationale and clinical settings in which the agents have been tested.
More recent news documents a shift in corporate direction. A September 2024 press release announces the termination of clinical studies for ONCT-534 and ONCT-808, the discontinuation of product development activities and the exploration of strategic alternatives. A July 2025 release reports the sale of the zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc. and states that a new executive will oversee the winddown of Oncternal’s operations. Together, these items form a historical record of how the ONCT story moved from active clinical development toward asset sales and an operational wind-down.
Users interested in ONCT news can review this stream to understand the company’s investigational programs, clinical milestones, strategic reviews and the subsequent wind-down steps described by Oncternal in its own announcements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.